<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200919048755N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-11-19</date_registration>
      <primary_sponsor>Tabriz University of Medical Sciences</primary_sponsor>
      <public_title>A randomized clinical trial of chlorhexzidine alcohol 4% compared with povidin Iodine 10% for vaginal scrub in gynecologic surgeries: complications and microbial flora</public_title>
      <acronym></acronym>
      <scientific_title>A randomized clinical trial of chlorhexzidine alcohol 4% compared with povidin Iodine 10% for vaginal scrub in gynecologic surgeries: complications and microbial flora</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-02-19</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>100</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/51028</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The sampling method will be as follows: first, using a table of random numbers, a sequence of letters A and B. The same number of statistical samples will be produced equally for the two experimental and control groups. Anti-diaphonic solutions are marked with two English letters A and B and according to the sequence of letters created, they will be used in two ways depending on the type of intervention (solution) in both case and control groups and the solution symbol used on the data sheet collection will be recorded, Blinding description: The sampling method will be as follows: first, using a table of random numbers, a sequence of numbers;The same number of statistical samples will be produced equally for the two experimental and control groups. Anti-septic  solutions are marked with two English letters A and B and according to the sequence of letters created, they will be used in two ways depending on the type of intervention (solution) in both case and control groups and the solution symbol used on the sheet. Data collection will be recorded.</study_design>
      <phase>3</phase>
      <hc_freetext>Infection of the vaginal Scrub site in gynecological surgeries.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Chlorhexidine alcohol will contain 4% alcohol. Due to the fact that this antiseptic solution does not exist in our country, it will be prepared and delivered by a clinical pharmacist with the mentioned percentage in the Faculty of Pharmacology of Tabriz University of Medical Sciences. In each patient in three stages, before the operation, immediately after the operation (in the first minute)  and then at the end of the operation,scrub with antiseptic solution using a sterile swab will be done, sampling of the vaginal walls and fornixes is prepared and transferred to the transport environment and Will be sent for microbial culture by one of the laboratory personnel.The operation site will be examined for local complications such as burning, inflammation, redness, scaling, and ulceration:immediately after the use of antiseptic, at the end of the operation, and in the morning after the operation by a trained nurse and will be recorded in the data sheet. Intervention 2: Control group: Povidine iodine 10%.In each patient in three stages, before the operation, immediately after the operation (in the first minute)  and then at the end of the operation,scrub with antiseptic solution using a sterile swab will be done, sampling of the vaginal walls and fornixes is prepared and transferred to the transport environment and Will be sent for microbial culture by one of the laboratory personnel.The operation site will be examined for local complications such as burning, inflammation, redness, scaling, and ulceration:immediately after the use of antiseptic, at the end of the operation, and in the morning after the operation by a trained nurse and will be recorded in the data sheet.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Maryam Vaezi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Number29,6th Dahmetri,Mollasadra Blvd,Daneshgah Alley,Tabriz city</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5165943333</zip>
        <telephone>+98 41 3544 7593</telephone>
        <email>hfallah.tbz@gmail.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Maryam Vaezi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Number29,6th dahmetri,Mollasadra Blvd,Daneshgah Alley,Tabriz city</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5165943333</zip>
        <telephone>+98 41 3544 7593</telephone>
        <email>hfallah.tbz@gmail.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients referred to Al-Zahra Hospital in Tabriz and candidates for elective vaginal surgery
Consent to participate in the study</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Hypersensitivity to povidine iodine or chlorhexidine alcohol
Evidence of active infection at the site of surgery
Having systemic diseases predisposing to infections such as diabetes or immunodeficiency diseases such as HIV
Taking cytotoxic drugs and corticosteroids in the last 6 months
Existence of active wound or laceration at the operation site
BmI&gt;30
Discharge of the patient on the day of surgery</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Chlorhexidine alcohol will contain 4% alcohol. Due to the fact that this antiseptic solution does not exist in our country, it will be prepared and delivered by a clinical pharmacist with the mentioned percentage in the Faculty of Pharmacology of Tabriz University of Medical Sciences. In each patient in three stages, before the operation, immediately after the operation (in the first minute)  and then at the end of the operation,scrub with antiseptic solution using a sterile swab will be done, sampling of the vaginal walls and fornixes is prepared and transferred to the transport environment and Will be sent for microbial culture by one of the laboratory personnel.The operation site will be examined for local complications such as burning, inflammation, redness, scaling, and ulceration:immediately after the use of antiseptic, at the end of the operation, and in the morning after the operation by a trained nurse and will be recorded in the data sheet.</i_keyword>
      <i_keyword>Control group: Povidine iodine 10%.In each patient in three stages, before the operation, immediately after the operation (in the first minute)  and then at the end of the operation,scrub with antiseptic solution using a sterile swab will be done, sampling of the vaginal walls and fornixes is prepared and transferred to the transport environment and Will be sent for microbial culture by one of the laboratory personnel.The operation site will be examined for local complications such as burning, inflammation, redness, scaling, and ulceration:immediately after the use of antiseptic, at the end of the operation, and in the morning after the operation by a trained nurse and will be recorded in the data sheet.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Povidine iodine disinfectant power. Timepoint: Before and immediately after the scrub (in the first minute). Method of measurement: The method will be that in both groups of patients, before scrub and immediately after it (in the first minute) microbial culture using a sterile swab and transfering it to a transport environment, based on the type and count of microorganisms will be done. The extent of vaginal microbial load reduction after the use of chlorhexidine 4% and betadine 10% solution will be determined and the data will be analyzed.</prim_outcome>
      <prim_outcome>Durability of chlorhexidine alcohol effect. Timepoint: Before and immediately after the scrub (in the first minute). Method of measurement: To compare the shelf life of the disinfectant solution or its inactivation during bleeding at the end of surgery (in the first minute after surgery), re-sampling for culture (in the first minute) using a sterile swab and transferring it to a transport medium, will be done .</prim_outcome>
      <prim_outcome>Durability of povidone iodine effect. Timepoint: Before and immediately after the scrub (in the first minute). Method of measurement: To compare the shelf life of the disinfectant solution or its inactivation during bleeding at the end of surgery (in the first minute after surgery), re-sampling for culture (in the first minute) using a sterile swab and transferring it to a transport medium, will be done.</prim_outcome>
      <prim_outcome>Side effects of Povidine-iodine. Timepoint: Immediately after using the solution and at the end of the operation and in the morning after the operation. Method of measurement: Observation and examination of the vulva and vagina in terms of local complications occurred in the mentioned solution based on the severity of the complication (burning, erythema, swelling and inflammation, scaling, scarring, etc.) based on the design questionnaire,immediately after using The solution ,at the end of the operation and in the morning after the operation. redness and burning at the site is considered mild complication, moderate complication is in case of scaling, and severe complication is in case of ulceration.</prim_outcome>
      <prim_outcome>Side effects of chlorhexidine alcohol. Timepoint: Immediately after using the solution and at the end of the operation and in the morning after the operation. Method of measurement: Observation and examination of the vulva and vagina in terms of local complications occurred in the mentioned solution based on the severity of the complication (burning, erythema, swelling and inflammation, scaling, scarring, etc.) based on the design questionnaire,immediately after using The solution ,at the end of the operation and in the morning after the operation. redness and burning at the site is considered mild complication, moderate complication is in case of scaling, and severe complication is in case of ulceration.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tabriz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-02-17</approval_date>
        <contact_name>Ethics committe of Tabriz University of Medical Sciences</contact_name>
        <contact_address>Number29,6th dahmetri,mollasadra Blvd,Daneshgah Alley,Tabriz city Tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
